Sun Pharmaceuticals Industries Ltd. Vs Commissioner of GST & Central Excise (CESTAT Chennai)
Introduction: The recent order from the Customs, Excise, and Service Tax Appellate Tribunal (CESTAT) Chennai in the case of Sun Pharmaceuticals Industries Ltd. vs. Commissioner of GST & Central Excise has brought significant relief to the pharmaceutical giant. The appeal contested the Commissioner’s order, and CESTAT Chennai ruled in favor of Sun Pharma regarding the product ‘Danazol.’
1. Background of the Case:
- Sun Pharmaceuticals had been clearing the product ‘Danazol’ without paying duty, claiming exemption under Sl. No. 47A of Notification No. 4/2006-CE dated 1.3.2006. The dispute arose when the department contested that ‘Danazol’ should be classified under Sl. No. 47B, subject to certain conditions.
2. Department’s Allegations:
- The department issued Show Cause Notices, asserting that Sun Pharma was not eligible for exemption as the product was supplied to other manufacturers without adhering to specified rules. Duty demands were raised, and penalties were imposed.
3. Order by Commissioner (Appeals):
- The Commissioner (Appeals) upheld the duty demands but set aside the penalties in the common Order in Appeal No. 8 to 12/2014 (P) dated 6.1.2014. The appellant, Sun Pharma, was dissatisfied with the duty demands and approached CESTAT Chennai.
4. Two Key Issues Considered:
(i) Whether ‘Danazol’ qualifies for unconditional exemption under Sl. No. 47A or falls under Sl. No. 47B.
(ii) If the product is exempted under Sl. No. 47A, the treatment of common input credit under Rule 6(3) of CENVAT Credit Rules, 2004.
5. CESTAT’s Decision on Classification:
- CESTAT Chennai referred to previous judgments and held that since ‘bulk drugs’ and ‘drugs and medicines’ were not defined in the Notification, the definition under the Drugs (Price Control) Order, 1995 was applicable. ‘Bulk drugs’ were considered a subset of ‘drugs,’ making Sun Pharma eligible for Sl. No. 47A.
6. Treatment of Input Credit:
